Skip to main content
. 2013 Jan 24;168(4):1015–1029. doi: 10.1111/bph.12005

Figure 4.

Figure 4

Effects of PKA activation on CGRP release. (A) Effects of the PKA activator forskolin in the presence of the PDE inhibitor IBMX in the spinal cord homogenate. IBMX alone did not evoke CGRP release (data not shown). Forskolin evoked CGRP release was inhibited by BCTC (1 μM). (B) Responses to capsaicin in the absence and in the presence of 30 μM forskolin + IBMX (100 μM). In the presence of forskolin + IBMX there is a 1.8-fold shift in the curve to capsaicin. 30 μM FSK and IBMX evoked a basal CGRP release of 12.7 ± 2.5%. Each data point represents the mean release ± SEM from at least three separate experiments. (C) Forskolin potentiation of PDBu responses – PDBu tested alone and in the presence of 30 μM forskolin and 100 μM IBMX. Data are displayed as a percentage of 0.3 μM capsaicin control minus relevant basal. Each data point represents the mean release ± SEM from at least three separate experiments.